<DOC>
	<DOCNO>NCT01898598</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study ass efficacy safety vismodegib surgery patient basal cell carcinoma . Patients randomize receive oral daily dos vismodegib 150 mg match placebo . The anticipated time study drug treatment 12 week .</brief_summary>
	<brief_title>A Study Vismodegib With Surgery Patients With Previously Untreated Basal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Adult patient , &gt; =18 year age Diagnosis noninfected , recurrent , previously untreated basal cell carcinoma Free significant physical abnormality ( e.g. , tattoo ) target basal cell carcinoma site Willing able participate study outpatient agreement make frequent visit clinic treatment followup period comply study requirement Prior treatment vismodegib Known hypersensitivity study drug excipients Any metastatic basal cell carcinoma Any locally advance basal cell carcinoma consider inoperable medical contraindication surgery Evidence clinically significant unstable disease condition ( e.g. , cardiovascular , immunosuppressive , hematologic ) Any dermatological disease target basal cell carcinoma site may cause difficulty examination Recent , current , planned participation another experimental drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>